アオキ サダオ
Sadao Aoki
青木 定夫 所属 新潟薬科大学 医療技術学部 臨床検査学科 職種 教授 |
|
言語種別 | 英語 |
発行・発表の年月 | 2016/06 |
形態種別 | 論文 |
査読 | 査読あり |
標題 | Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. |
執筆形態 | 共著 |
掲載誌名 | International journal of hematology |
掲載区分 | 国外 |
巻・号・頁 | 103(6),pp.686-92 |
著者・共著者 | Masaki Yasufumi, Kawabata Hiroshi, Takai Kazue, Kojima Masaru, Tsukamoto Norifumi, Ishigaki Yasuhito, Kurose Nozomu, Ide Makoto, Murakami Jun, Nara Kenji, Yamamoto Hiroshi, Ozawa Yoko, Takahashi Hidekazu, Miura Katsuhiro, Miyauchi Tsutomu, Yoshida Shinichirou, Momoi Akihito, Awano Nobuyasu, Ikushima Soichiro, Ohta Yasunori, Furuta Natsue, Fujimoto Shino, Kawanami Haruka, Sakai Tomoyuki, Kawanami Takafumi, Fujita Yoshimasa, Fukushima Toshihiro, Nakamura Shigeo, Kinoshita Tomohiro, Aoki Sadao |
概要 | TAFRO syndrome is a systemic inflammatory disorder characterized by thrombocytopenia, anasarca including pleural effusion and ascites, fever, renal insufficiency, and organomegaly including hepatosplenomegaly and lymphadenopathy. Its onset may be acute or sub-acute, but its etiology is undetermined. Although several clinical and pathological characteristics of TAFRO syndrome resemble those of multicentric Castleman disease (MCD), other specific features can differentiate between them. Some TAFRO syndrome patients have been successfully treated with glucocorticoids and/or immunosuppressants, including cyclosporin A, tocilizumab and rituximab, whereas others are refractory to treatment, and eventually succumb to the disease. Early and reliable diagnoses and early treatments with appropriate agents are essential to enhancing patient survival. |
DOI | 10.1007/s12185-016-1979-1 |
ISSN | 1865-3774 |
PMID | 27084250 |